Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares
January 25 2016 - 1:37AM
Transparency notification to Galapagos NV (Euronext &
NASDAQ: GLPG) - Gilead Sciences, Inc. (NASDAQ:
GILD) crosses a 10% threshold of Galapagos' voting rights, to a
14.75% shareholding in Galapagos.
Pursuant to Belgian transparency legislation1, Galapagos NV
("Galapagos") and Gilead Sciences, Inc. ("Gilead") have filed a
joint transparency notification on 22 January 2016.
The transparency notification announces that Gilead, as a result of
its entirely-controlled subsidiary Gilead Biopharmaceutics Ireland
Unlimited Company subscribing to a capital increase and thus
receiving 6,760,701 new Galapagos shares on
19 January 2016, indirectly holds 14.75% of the current
45,837,043 outstanding Galapagos shares. Gilead therefore
crossed a 10% threshold of Galapagos' voting rights on
19 January 2016. Furthermore, Galapagos and Gilead
are acting in concert as a result of standstill and lock-up
provisions with respect to Galapagos shares held by Gilead
contained in their global collaboration agreement for the
development and commercialization of the JAK1-selective inhibitor
filgotinib. The full transparency notice is available for
viewing on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action. Our
pipeline comprises three Phase 2, four Phase 1, five pre-clinical,
and 20 discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have
discovered and developed filgotinib: in collaboration with Gilead
we aim to bring this JAK1-selective inhibitor for inflammatory
indications to patients all over the world. Galapagos is
focused on the development and commercialization of novel medicines
that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Galapagos Contacts
Investors: Media:
Elizabeth
Goodwin Evelyn
Fox VP IR & Corporate
Communications Director
Communications +1 781 460
1784
+31 6 53 591 999
ir@glpg.com
communications@glpg.com
Galapagos Forward-Looking Statements
This release may contain forward-looking statements.
Galapagos cautions the reader that forward-looking statements are
not guarantees of future performance. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition
and liquidity, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or
future results, financial conditions and liquidity, performance or
achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos' results,
performance, financial condition and liquidity, and the development
of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. Among the factors that may
result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements,
Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of our product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's
Securities and Exchange Commission filing and reports, including in
the company's prospectus filed with the Securities and Exchange
Commission on May 14, 2015 and subsequent filings and reports filed
by the company with the Securities and Exchange Commission.
Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market
Transparancy notification - Gilead holds 14.75% Galapagos shares
http://hugin.info/133350/R/1980910/725708.pdf
HUG#1980910
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024